Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

40.60 -0.43 (-1.05%)
Streaming Delayed Price Updated: 1:36 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
The stock is coming off a strong year. 
Via The Motley Fool
Topics Intellectual Property
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
Via Chartmill
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
Via MarketBeat
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
Exelixis (EXEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Stocks That Could Soar This Year ↗
These innovative biotechs could have plenty of upside ahead. 
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Via Chartmill
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
These could be the next biotech giants. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
EXELIXIS INC (EXEL) combines strong fundamentals with a bullish technical setup. Its robust earnings growth, zero debt, and accelerating EPS align with a stock poised for a potential breakout. 
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Preview: Exelixis's Earnings ↗
 
Via Benzinga
News headline image
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Exelixis (EXEL) is a financially strong oncology biotech with high profitability, zero debt, and a low valuation relative to its earnings growth, fitting key value investing principles. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗
Exelixis (EXEL) exemplifies GARP investing with strong oncology earnings growth, a debt-free balance sheet, and a valuation discounted versus biotech peers. 
Via Chartmill
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
These drugmakers are poised to profit from their innovative engines. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
Discover EXELIXIS (EXEL), a value stock with strong profitability, zero debt, and solid growth, trading at an attractive discount to its industry peers. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet. 
Via Chartmill
News headline image
S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over... 
Via MarketMinute
Topics Economy Regulatory Compliance Stocks
News headline image
Global Markets Rally on Hopes for US Government Shutdown Resolution
Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
What's Driving the Market Sentiment Around Exelixis Inc? ↗
 
Via Benzinga
News headline image
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗
Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector. 
Via Chartmill
News headline image
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.